<bill session="117" type="h" number="4278" updated="2022-12-31T04:58:12Z">
  <state datetime="2021-06-30">REFERRED</state>
  <status>
    <introduced datetime="2021-06-30"/>
  </status>
  <introduced datetime="2021-06-30"/>
  <titles>
    <title type="official" as="introduced">To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.</title>
    <title type="display">To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="M001210"/>
  <cosponsors>
    <cosponsor bioguide_id="H001086" joined="2021-06-30"/>
  </cosponsors>
  <actions>
    <action datetime="2021-06-30">
      <text>Introduced in House</text>
    </action>
    <action datetime="2021-06-30" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2021-07-01">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-02-13T21:22:12Z" status="Introduced in House">This bill requires the Government Accountability Office to study and report on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers.</summary>
</bill>
